MESO
NASDAQMesoblast Limited
News · 26 weeks32-17%
2026-04-192026-10-11
Mix1590d
- SEC Filings9(60%)
- Other6(40%)
Latest news
25 items- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil ProductNEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of its FDA-approved mesenchymal stromal cell (MSC) product Ryoncil® (remestemcel-L-rknd). The TIBA assay will ensure sufficient sensitivity to detect any shifts in potency of the commercial product that could arise during changes in manufacturing processes or production in ne
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 20-F filed by Mesoblast Limited20-F - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Reports Substantial Revenue Growth to US$120MRYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: "We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. The financial result is a product of continued growth in RYONCIL market adoption and focus on disciplined c
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Financial Results and Corporate Update WebcastNEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026. The webcast will begin at 6.30pm EDT, Wednesday, August 26; 8.30am AEST, Thursday, August 27, 2026. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2026/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of sever
- PRMesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back PainNEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with the inflammatory condition of degenerative disc disease. The major milestone was achieved with 350 patients randomized and treated with either an intra-discal injection of rexlemestrocel-L or sham injection. Total patient numbers treated increased from 300 to 350 after strong demand from trial investigators to have their patients enrolled in the inn
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product LaunchExpanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report for Quarter Ended June 30, 2026 (Appendix 4C) NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the fourth fiscal quarter ended June 30, 2026. "We are very pleased with the continued momentum in uptake of Ryoncil® in children with life-threatening steroid-refractory acute GvHD across major U.S. pediatr
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back PainNEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial. Silviu Itescu, Chief Executive of Mesoblast, said: "Completing our target of treating at least 300 patients in the placebo-controlled pivotal back pain
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Obrien James Michael4 - MESOBLAST LTD (0001345099) (Issuer)
- PRRyoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. "We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial projections," said Mesoblast Chief Executive Dr. Silviu Itescu. Dr. Itescu added: "We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major U.S. pediatric centers. Our capital position is strong, operati
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADsNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a modular review of its BLA for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD). Rexlemestrocel-L has received Orphan Drug Designation for prevention of life-threatening major mucosal bleeding events and has Regenerative Medicine Adva
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Draws US$50 Million from Five-Year Non-Dilutive FacilityOptimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it drew down US$50 million from its five-year facility provided by existing Mesoblast shareholder and director Dr. Gregory George. Mesoblast had US$122 million cash at March 30, 2026. In aggregate Mesoblast is well funded to invest in its commercial operations and growth pipeline, and optimize its capital structure by retiring the higher cost NovaQuest Capital Management LLC debt facility
MESO FAQ
7 questionsWhat does Mesoblast Limited do?
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic...Where does MESO stock trade?
Mesoblast Limited (MESO) is listed on NASDAQ.What sector and industry is MESO in?
Mesoblast Limited operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Mesoblast Limited go public?
Mesoblast Limited (MESO) completed its IPO in 2015.What are analysts saying about MESO?
Mesoblast Limited has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2025-11-25. Recent price targets range from $1100.00 to $1200.00.What companies are similar to MESO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare MESO side-by-side with any of them on Quantisnow.How can I track MESO on Quantisnow?
Quantisnow aggregates Mesoblast Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MESO to receive live email and push alerts on every new disclosure.